TG in PPP of patients with NSTEMI treated with ticagrelor in the presence or absence of VLD rivaroxaban. (A) Representative tracings and (B) arithmetic means ± SEM (n = 20) of lag time, TTP, peak (thrombin), and velocity of TG in PPP of patients with NSTEMI before (baseline) and after medication with ticagrelor + ASA for 1 and 2 days (d1 and d2) in the absence (DMSO) or presence of 40 ng/mL rivaroxaban (in vitro). **P < .01 and ***P < .001 indicate statistically significant differences from solvent control at the indicated time point. #P < .05, ##P < .01, and ###P < .001 indicate significant differences from baseline.